Amylin Pharmaceuticals Shareholder?

Last Updated on May 1, 2020

Investigation Complete

Comments |

At A Glance

This Alert Affects
Amylin Pharmaceuticals Shareholders
Allegations have surfaced that Amylin Pharmaceuticals failed to notify shareholders that it rejected a buyout offer from Bristol-Myers Squibb for $22 per share yet the insiders then awarded themselves new low-priced options.
Amylin Pharmaceuticals
Additional Details
In a shareholder derivative action, a shareholder theoretically files a claim on behalf of the corporation to protect its investors and to holder officers and directors accountable for improper management of the company.